Immunic Inc, developing a multiple sclerosis treatment, has appointed Jon Congleton to its board of directors. The executive played a key role in the US launch of Teva Pharmaceuticals Industries’ treatment Copaxone for relapsing forms of MS and led the US operations when Copaxone became the number one prescribed MS treatment in the US. Immunic’s lead product vidofludimus is currently in a Phase 3 trial with top line data expected at the end of 2026. Mr Congleton is currently chief executive officer of Mineralys Therapeutics Inc and has 40 years of experience across cardiovascular, gastrointestinal and central nervous system biopharmaceutical organisations, holding commercial leadership positions and advancing innovative therapies.
Immunic announced the appointment on 31 March 2026.
Copyright 2026 Evernow Publishing Ltd.